Payment overview · 2025
General Payments
$80.37
4 reported records · 3 companies
Healthcare provider profile · identity verified
Wesley Jay Driggers, MD, PHD
Allopathic & Osteopathic Physicians|Family Medicine · PORT ORANGE, FL · NPI 1891790309
Verified facts
What the public records show
CMS Open Payments records show Wesley Jay Driggers, MD, PHD received $80.37 in general payments during 2025 across 4 reported records.
Exact Sciences Corporation accounted for 49.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Shingrix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.94 | 49.7% | 2 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $25.32 | 31.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.11 | 18.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $80.37 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $39.94 | 2 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $25.32 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 17 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
17 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 511 | 150 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 416 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 357 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 288 | 86 |
| Lisinopril | Lisinopril | 268 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 204 | 65 |
| Losartan Potassium | Losartan Potassium | 166 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 165 | 53 |
| Metformin Hcl | Metformin Hcl | 153 | 45 |
| Gabapentin | Gabapentin | 147 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 144 | 29 |
| Telmisartan | Telmisartan | 141 | 41 |
| Omeprazole | Omeprazole | 132 | 42 |
| Metformin Hcl Er | Metformin Hcl | 129 | 43 |
| Famotidine | Famotidine | 121 | 46 |
| Tramadol Hcl | Tramadol Hcl | 114 | 44 |
| Lorazepam | Lorazepam | 105 | 28 |
| Farxiga | Dapagliflozin Propanediol | 104 | 19 |
| Alendronate Sodium | Alendronate Sodium | 103 | 41 |
| Eliquis | Apixaban | 98 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 41 |
| Ezetimibe | Ezetimibe | 97 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 26 |
| Prednisone | Prednisone | 89 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 21 |
| Dexamethasone | Dexamethasone | 82 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 25 |
| Methocarbamol | Methocarbamol | 76 | 39 |
| Simvastatin | Simvastatin | 71 | 20 |
| Alprazolam | Alprazolam | 70 | 21 |
| Allopurinol | Allopurinol | 69 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 41 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 63 | 43 |
| Sertraline Hcl | Sertraline Hcl | 63 | 17 |
| Celecoxib | Celecoxib | 60 | 23 |
| Potassium Chloride | Potassium Chloride | 60 | 21 |
| Carvedilol | Carvedilol | 55 | 15 |
| Trazodone Hcl | Trazodone Hcl | 55 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 15 |
| Bupropion Xl | Bupropion Hcl | 51 | 14 |
| Furosemide | Furosemide | 51 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | 14 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 50 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 33 |
| Glipizide | Glipizide | 49 | 17 |
| Propranolol Hcl | Propranolol Hcl | 49 | 14 |
| Azithromycin | Azithromycin | 48 | 33 |
| Glimepiride | Glimepiride | 46 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 44 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 41 | suppressed |
| Meloxicam | Meloxicam | 39 | 11 |
| Bydureon Bcise | Exenatide Microspheres | 38 | suppressed |
| Lovastatin | Lovastatin | 38 | 11 |
| Temazepam | Temazepam | 38 | suppressed |
| Spironolactone | Spironolactone | 37 | 11 |
| Atenolol | Atenolol | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 34 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 24 |
| Morphine Sulfate Er | Morphine Sulfate | 31 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | 14 |
| Clonazepam | Clonazepam | 25 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 25 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | 12 |
| Montelukast Sodium | Montelukast Sodium | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 15 |
| Estradiol | Estradiol | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Zaleplon | Zaleplon | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Fluconazole | Fluconazole | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 11 |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 11 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Nexletol | Bempedoic Acid | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $80.37 · 4 records | Exact Sciences Corporation | Cologuard Collection Kit, Indigo System, SHINGRIX | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error